Institutional members access full text with Ovid®

Share this article on:

Bipolar disorders, type 2 diabetes mellitus, and the brain

Hajek, Tomasa,b; McIntyre, Rogerc; Alda, Martina,b

Current Opinion in Psychiatry: January 2016 - Volume 29 - Issue 1 - p 1–6
doi: 10.1097/YCO.0000000000000215
MOOD AND ANXIETY DISORDERS: Edited by Sidney H. Kennedy and Hans-Ulrich Wittchen

Purpose of review Type 2 diabetes mellitus (T2DM) negatively affects brain structure and function. Meta-analytical data show that relative to age and sex matched non-psychiatric controls, patients with bipolar disorders have double the risk of T2DM. We review the evidence for association between T2DM and adverse clinical and brain imaging changes in bipolar disorders and summarize studies investigating effects of diabetes treatment on psychiatric and brain outcomes.

Recent findings Participants with bipolar disorders and T2DM or insulin resistance demonstrate greater morbidity, chronicity and disability, and lower treatment response to Li. Bipolar disorders complicated by insulin resistance/T2DM are associated with smaller hippocampal and cortical gray matter volumes and lower prefrontal N-acetyl aspartate (neuronal marker). Treatment of T2DM yields preservation of brain gray matter and insulin sensitizers, such as pioglitazone, improve symptoms of depression in unipolar or bipolar disorders.

Summary T2DM or insulin resistance frequently cooccur with bipolar disorders and are associated with negative psychiatric clinical outcomes and compromised brain health. This is clinically concerning, as patients with bipolar disorders have an increased risk of metabolic syndrome and yet often receive suboptimal medical care. At the same time treatment of T2DM and insulin resistance has positive effects on psychiatric and brain outcomes. These findings create a rich agenda for future research, which could enhance psychiatric pharmacopeia and directly impact patient care.

aDepartment of Psychiatry, Dalhousie University, Halifax, Canada

bNational Institute of Mental Health, Klecany, Czech Republic

cDepartment of Psychiatry, University of Toronto, Toronto, Canada

Correspondence to Tomas Hajek, MD, PhD, Department of Psychiatry, Dalhousie University, QEII HSC, A.J. Lane Bldg., Room 3093, 5909 Veteran's Memorial Lane, Halifax, NS B3H 2E2, Canada. Tel: +902 473 8299; fax: +902 473 1583; e-mail: tomas.hajek@dal.ca

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.